Analysts expect Evolv Technologies to report a Q2 2026 loss of $0.06 per share on revenue of $29.4 million, with the current $3.12 stock price trading significantly below the $6.25 consensus price target.
The primary focus for investors this quarter is the growth trajectory of Annual Recurring Revenue (ARR), which serves as a leading indicator for the company’s transition toward a software-heavy recurring revenue model.
Markets are also monitoring gross margin improvements as the company scales its AI-based security screenings across schools, hospitals, and stadiums. Despite recent volatility, Evolv has benefited from increased security spending, though the long-term path to GAAP profitability remains the central concern for institutional investors.